N-BOC-4,4-difluoro-L-proline | CAS:203866-15-3

We serve N-BOC-4,4-difluoro-L-proline CAS:203866-15-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
N-BOC-4,4-difluoro-L-proline

Chemical Name:N-BOC-4,4-difluoro-L-proline
CAS.NO:203866-15-3
Synonyms:N-t-BOC-4,4-Difluoro-L-Proline
(S)-1-(tert-Butoxycarbonyl)-4,4-difluoropyrrolidine-2-carboxylic acid
(2S)-4,4-difluoro-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid
4,4-Difluoro-1-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-proline
1-(tert-Butoxycarbonyl)-4,4-difluoro-L-proline
N-(tert-Butoxycarbonyl)-4,4-difluoro-L-proline
Molecular Formula:C10H15F2NO4
Molecular Weight:251.22700
 
Physical and Chemical Properties:
Density:1.31
Melting point:120-124ºC
Boiling point:340ºC
Index of Refraction:1.474
 
Specification:
Appearance:White solid
Assay:≥97.0%
Melting point:126-128ºC
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:N-Boc-4,4-difluoro-L-proline is a reagent used in the preparation of structure-activity relationship and pharmacokinetics of pyrrolotriazines as pan-Aurora kinase inhibitors and anti tumor agents.



Contact us for information like N-BOC-4,4-difluoro-L-proline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Molecular Formula:C10H15F2NO4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Molecular Formula:C10H15F2NO4 Use and application,Molecular Formula:C10H15F2NO4 technical grade,usp/ep/jp grade.


Related News: Our previous work with Retrogenix validated their technology as a uniquely powerful approach for antibody target deconvolution, and we look forward to working with Retrogenix to enhance our growing pipeline of antibody candidates.”2,3-Difluoropyridine-4-carboxylic acid manufacturer Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.[dimethylamino-(1-oxidopyridin-1-ium-2-yl)sulfanylmethylidene]-dimethylazanium,hexafluorophosphate supplier Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.N-tert-butyl-6-chloro-4-(o-tolyl)nicotinamide vendor Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.